linjc16/ctgov huggingface dataset:
Gender Bias and Overtreatment in Primary Care

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze if there are differences between men and women in the frequency of ignoring Do not do recommendations in primary care setting.

Detailed Description
-----------------
First, using the Delphi technique, a consensus will be reached on those Do Not Do recommendations that should be included in the retrospective analysis study. The selection criteria for these recommendations will be if they are about pharmacological treatments, considered to persist in clinical practice in primary care, their relationship with factors associated with sex and gender, and if ignoring the Do not do recommendation could cause a serious adverse event. Second, a retrospective cohort study will be carried out including patients who attended primary care consultation in Alicante from 1st January 2022 to 31st December 2022. Data source will be the electronic record management system of the autonomous community of Valencia (named ABUCASIS), and they will be provided by the Ambulatory Assistance Information System (SIA-GAIA). Investigators will analyze the frequency of ignoring the Do not do recommendations previously selected by consensus by sex and age range.

Official Title
-----------------
Epidemiological Study on Gender Bias and Overtreatment in Primary Care Setting

Conditions
-----------------
Any Condition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Attending primary care consultation from 1 January 2022 to 31 December 2022. Adults Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of female patients who were recommended do not do | Number of female patients who were recommended do not do | From 1st January 2022 to 31 December 2022 | 
| Number of male patients who were recommended do not do | Number of male patients who were recommended do not do | From 1st January 2022 to 31 December 2022 |
Management of Pilon Fractures With Versus Without Fibula Fixation

Study Overview
=================
Brief Summary
-----------------
Management of pilon fractures with versus without fibula fixation

Detailed Description
-----------------
Comparing results with or without fibular fixation in : Rate of bone union . Functional return ( clinical outcomes) Alignment of lower limb.

Official Title
-----------------
Management of Pilon Fractures With Versus Without Fibula Fixation

Conditions
-----------------
Pilon Fracture

Intervention / Treatment
-----------------
* Device: Dynamic compression plate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with metaphyseal non rotational pilon or distal tibia : age ( 18 _ 65 ) No skin troubles No infections Non-dibetic patients. Exclusion Criteria: Patients who will not complete their follow up. Skin troubles Infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Management of pilon fractures with fibula fixation | Device: Dynamic compression plate<br>* Fixation of fibula in some cases with dynamic compression plate<br>|
| 2<br>Management of pilon fracture without fibula fixation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fracture healing and bone union | by RUST score | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidece and rate of complications | Incidence and rate of complications (e.g. non-union, skin breakdown , infections and postraumatic malaligment) by AOFAS score | Baseline |
PDA Stent in Neonates With PDA Dependent Pulmonary Circulation

Study Overview
=================
Brief Summary
-----------------
After echocardiography confirmation of PDA dependent pulmonary circulation in cyanotic neonates, catheter-guided PDA stent implantation will be done. Under general Anasthesia and after discontinuation of prostaglandin 4-6 hours before procedure, obtain vascular access and unfractionated heparin is given, then duct is accessed via a cut pig-tail or Judkins right [JR] catheter, and is crossed by PTCA wire to be carefully placed in the left or right branch pulmonary arteries, choose proper stent diameter and length, place the stent and confirm it's position, NICU admission for the neonate with heparin infusion for 24-48 hrs and acetylsalicylic acid is given then follow up the patient by pulse oximeter and echocardiography

Official Title
-----------------
Outcomes for Patent Ductus Arteriosus Stenting in Neonates With Duct-Dependent Pulmonary Circulation: A Prospective Study at Sohag University Hospital

Conditions
-----------------
Neonatal Cyanosis Due to PDA Dependent Pulmonary Circulation

Intervention / Treatment
-----------------
* Device: Catheter-guided PDA stent implantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates and young infants with duct dependent pulmonary circulation Exclusion Criteria: Untreated sepsis. Coagulopathy. PDA dependent systemic circulation.

Ages Eligible for Study
-----------------
Minimum Age: 1 Hour
Maximum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cyanotic neonate<br>Cyanotic neonates with PDA dependent pulmonary circulation will be treated with catheter guided PDA stent implantation to keep duct patency and improve oxygen saturation | Device: Catheter-guided PDA stent implantation<br>* PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation<br>* Other names: PDA stent;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Oxygen saturation | Using pulse oximeter to assess oxygen saturation | Change in oxygen saturation within 24 hours | 
| Evaluation of duct patency | Using echocardiography assess flow through the duct | 1 month |
Pediatric Post-operative Abdominal Wound Dehiscence in Association With Midline vs Other Incisions: A Prospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
This study is designed to see different abdominal incisions complication among neonates, infants and children and to find risk factors for developing wound dehiscence

Official Title
-----------------
Pediatric Post-operative Abdominal Wound Dehiscence in Association With Midline vs Other Incisions in Tertiary Care Setting Kabul Afghanistan: A Cohort Study

Conditions
-----------------
Wound Dehiscence, Incision

Intervention / Treatment
-----------------
* Procedure: laparatomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -all abdominal surgeries patient under 18-year-old. Exclusion Criteria: Umbilical hernia, redo laparatomy, laparoscopic surgery.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Age Group<br>Neonates Infants Children | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|
| Gender<br>Male Female | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|
| Selective/Emergency<br>Selective Emergency | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|
| Wound Class<br>Clean Clean-contaminated Contaminated Infected | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|
| Risk Factors<br>Yes No | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|
| Type of Incisions<br>Midline Trransverse Oblique | Procedure: laparatomy<br>* all abdominal procedures which are approached by different incisions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound dehiscence or burst abdomen | the overall outcome of the intervention (incisions) is wound dehiscence in different age groups, in gender, among who has or has no risk factors and among different wound class | one month after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
abdominal wound dehiscence, burst abdomen, pediatric abdominal incisions, children
Two-piece Zirconia Implants With Two Various Platforms

Study Overview
=================
Brief Summary
-----------------
24 patients with missing premolar teeth and healed sockets will be recruited. They will be randomized into two groups to supplied with tissue-level (n=12) or bone-level (n=12) 10-mm long 4-mm wide zirconia implants. Primary and secondary stabilities will be measured with International Stability Quotient (ISQ) device. After 3 months, ceramic crowns will be supplied. Implant survival rates and parameters in relation to periimplant soft-tissues and bone health and anatomy will be recorded and evaluated after 1, 3 and 5 years.

Official Title
-----------------
Comparison of Two-piece Zirconia Implants With Tissue-level and Bone-level Platform: Randomized Controlled Clinical Trial

Conditions
-----------------
Edentulous Alveolar Ridge

Intervention / Treatment
-----------------
* Device: Zirconia dental implants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single missing maxillary premolar Occlusal stability Good oral hygiene Good general health Exclusion Criteria: Oral mucosa pathology Dental caries Active periodontitis (non-treated) Systemic diseases and conditions that affect healing or immune capacity

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tissue-level<br>Two-piece zirconia implants with tissue-level platform will be supplied to the single gap premolar regions in maxillae. | Device: Zirconia dental implants<br>* Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.<br>|
| Experimental: Bone-level<br>Two-piece zirconia implants with bone-level platforms will be supplied to the single gap premolar regions in maxillae. | Device: Zirconia dental implants<br>* Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Crestal bone loss (mm) | Loss of marginal bone in mm | baseline, 1-year, 3-years, 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Probing depth (mm) | Probing pocket depth measured with periodontal probe | baseline, 1-year, 3-years, 5 years | 
| Bleeding on probing (BOP) | Bleeding provoked by probing | baseline, 1-year, 3-years, 5 years | 
| Volumetric tissue change | Sequential intraoral scanning | 1-year, 3-years, 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dental implants, zirconia, two-piece
Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
Nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postop-erative pain. The double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.

Official Title
-----------------
Comparison of Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Clinical Trial

Conditions
-----------------
Laparoscopic Cholecystectomy, Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Drug: normal Saline
* Drug: Dexamethasone
* Drug: Dexmedetomidine
* Drug: Combination of dexamethasone + dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged from 20 - 50 years ASA I OR II undergo laparoscopic cholecystectomy Exclusion Criteria: Patients with history of psychotic illnesses, Parkinson's disease motion disorder Smoker or history of chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br>received 20 ml normal saline | Drug: normal Saline<br>* Intraperitoneal route<br>|
| Active Comparator: dexamethasone group<br>received 8mg dexamethasone | Drug: Dexamethasone<br>* Intraperitoneal route<br>|
| Active Comparator: dexmedetomidine group<br>received dexmedetomidine 1mic/kg | Drug: Dexmedetomidine<br>* Intraperitoneal route<br>|
| Active Comparator: combined group<br>received combination of both 8mg dexamethasone+ dexmedetomidine 1mic/kg | Drug: Combination of dexamethasone + dexmedetomidine<br>* Intraperitoneal route<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients suffered from postoperative nausea and vomiting will be recorded in each group. |  | 24 hours postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antiemetic consumption | frequency of antiemetic consumption will be determined | 24 hours postoperatively |
Delirium Detection During Routine Patient Care

Study Overview
=================
Brief Summary
-----------------
Despite the presence of validated tests, there are still drawbacks to implementing delirium diagnosis tests in hospital wards. We developed a new, simple, easy to implement user friendly delirium diagnostic test that is likely to facilitate implementation in many departments. The present study will compare the new test to a well validated older test - 4AT.

Detailed Description
-----------------
Delirium is characterized by an acute onset altered mental status and/or a confusional state. Although delirium has been known since ancient times, the condition is often not diagnosed, documented, evaluated, and managed. Early detection of delirium in hospitalized patients may be critical, particularly on internal medicine wards, as mental deterioration in the elderly can be the first sign of preventable diseases and disorders that precipitate delirium. Nevertheless only 15%-35% of cases of delirium in hospitalized patients are identified by the treating staff and documented in the medical records. The main reasons for this shortcoming are insufficient awareness to emerging delirium, and excessive work load. We have recently developed and implemented in our Department of Internal Medicine a new diagnostic tool for delirium. This test, designated R&M, is based on a combination of RADAR (Recognizing Acute Delirium As part of your Routine), performed by the nurses during medication dispensing, and MOYB (Months Of the Year Backwards), performed by residents during the routine rounds in patients with positive RADAR. Both tests are online and saved in the patients' electronic records. The purpose of this study is to demonstrate non-inferiority of R&M compared to 4AT (Attention, Abbreviated mental test, Alertness, Acute onset Test), an old and well validated delirium recognition test. The sample size required for a sensitivity of 95% and a 95% confidence interval was calculated to be n=365, assuming delirium prevalence of >20% in elderly patients hospitalized in internal medicine wards.

Official Title
-----------------
Validation of a Viable Delirium Detection Test Performed by Nurses and Physicians During Routine Patient Care

Conditions
-----------------
Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - patients >70 yrs old, hospitalized in the department of internal medicine Exclusion Criteria: severe dementia

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of a viable delirium detection test care. | non-inferiority of a new delirium detection test (R&M) compared to 4AT. | ONE YEAR | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
4AT, DELIRIUM, DIAGNOSIS
PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Study Overview
=================
Brief Summary
-----------------
Colorectal cancer (CRC) is a highly heterogenous disease. It the third most commonly diagnosed cancer in the world and the second cause of death among cancer cases mortality. Its incidence is rising all over the world, especially in developing countries . In Egypt it is coming the seventh cancer in incidence according to World Health Organization (WHO, 2020). Although there is much improvement in the diagnosis and treatment, but CRC is still constituting a big impact on human life and health, so researchers are trying to find out new therapeutic targets . Programmed cell death protein 1 (PD-1) is an inhibitory receptor which is expressed on the surface of T lymphocytes during activation. Its role is to control T cell effector activity for various cellular responses as infections, autoimmune reactions, and cancer . Cancer cells develop PD-ligand1 (PD-L1) expression which is a transmembrane molecule belonging to B7 family. Its action is through PD-1/PD-L1 reaction, and causing invasion and metastasis of cancer cells by protecting it from immunosurveillance by inhibiting T cell effector function, leading to carcinogenesis and development of many cancers including colorectal cancer.

Official Title
-----------------
Immunohistochemical Expression of PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Conditions
-----------------
PDL1- Colorectal Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both endoscopic and excisional biopsy specimens. All the studied cases include sufficient materials for the immunohistochemical study. Complete clinical data Exclusion Criteria: Patients with recurrence of the primary tumor. Patients with a history of preoperative chemotherapy and/or radiotherapy. Insufficient or tiny tissue biopsies

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis and prognosis of colorectal carcinoma | Immunohistochemical expression of PDL1 in primary colorectal carcinoma | Two or three days after staining tissue sections with PDL1 antibody |